HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avoiding ‘Kiss Killers’ – GSK Offers German Consumers New Oral Hygiene Products For The Festival Season

Executive Summary

With Carnival season approaching in Germany, GlaxoSmithKline is helping German consumers to take care of their oral hygiene with new toothbrushes and its Zovirax Duo cold sore treatment. 

You may also be interested in...



GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.

Germany Marketing Round Up December 2018: New OTC Products For The Winter Cough and Cold Season

Five new OTC cough and cold products have hit the shelves in Germany this winter from Pari, Pohl Boskamp, Engelhard Arzneimittel, GSK and Dr Soldan.

Zovirax launched OTC in Germany

German consumers are now able to buy GlaxoSmithKline (GSK) Consumer Healthcare’s Zovirax Duo cold-sore treatment without a prescription.

Topics

Related Companies

UsernamePublicRestriction

Register

RS148448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel